Ranitidine Hydrochloride

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

40 API Suppliers, 32 USDMF, 14 CEP/COS, 2 JDMF, 5 EU WC, 47 KDMF, 11 NDC API, 7 Listed Suppliers, $ API Reference Price

INTERMEDIATES

1 Intermediates Suppliers

1 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

169 FDF Dossiers, 121 FDA Orange Book, 21 Europe, 8 Canada, 19 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 300MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 25MG BASE/ML, TABLET;ORAL - EQ 75MG BASE, TABLET;ORAL - EQ 150MG BASE

RELATED EXCIPIENT COMPANIES

5 Rochem International Inc, 8 SPI Pharma, 2 Seqens, 9 DKSH, 2 Jai Radhe Sales, 1 Pharm-RX Chemical, 7 Faran Shimi Pharmaceutical, 3 Boai NKY Pharmaceuticals Ltd, 15 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 4 ACG Worldwide, 13 Actylis, 1 Aeon Procare, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 16 BASF, 1 Bioplus Life Sciences, 1 Clariant, 10 Corel Pharma Chem, 6 DFE Pharma, 3 Finar, 9 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 29 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 10 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 1 Novo Excipients, 2 Pharmatrans-Sanaq, 8 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 32 Roquette, 13 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Vertellus, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

73 Fillers, Diluents & Binders, 49 Coating Systems & Additives, 30 Direct Compression, 28 Disintegrants & Superdisintegrants, 28 Thickeners and Stabilizers, 27 Controlled & Modified Release, 23 Film Formers & Plasticizers, 23 Taste Masking, 20 Parenteral, 20 Solubilizers, 19 Granulation, 17 Lubricants & Glidants, 17 Co-Processed Excipients, 17 Topical, 9 Chewable & Orodispersible Aids, 9 Empty Capsules, 8 Emulsifying Agents, 7 API Stability Enhancers, 5 Surfactant & Foaming Agents, 5 Coloring Agents, 5 Rheology Modifiers, 4 Vegetarian Capsules, 1 Soft Gelatin

DIGITAL CONTENT

3 DATA COMPILATION #PharmaFlow, 1 STOCK RECAP #PipelineProspector, 118 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

7 Finished Drug Prices, 3 Annual Reports

MARKET PLACE

18 APIs

18 APIs

PATENTS & EXCLUSIVITIES

15 Health Canada Patents

15 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 1 USP, 2 JP, 1 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 18703 / DOSAGE - TABLET;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
RANITIDINE HYDROCHLORIDE(UNII: BK76465IHM) (RANITIDINE - UNII:884KT10YB7)	RANITIDINE	300mg \| 150mg

Inactive Ingredients

Ingredient Name	GlaxoSmithKline LLC
CROSCARMELLOSE SODIUM(M28OL1HH48)
D&C YELLOW NO. 10(35SW5USQ3G)
FD&C YELLOW NO. 6(H77VEI93A8)
FERRIC OXIDE YELLOW(EX438O2MRT)
HYPROMELLOSE, UNSPECIFIED(3NXW29V3WO)
MAGNESIUM STEARATE(70097M6I30)
MICROCRYSTALLINE CELLULOSE(OP1R32D61U)
TITANIUM DIOXIDE(15FIX9V2JP)
TRIACETIN(XHX3C3X673)

Drug Product Composition: Ranitidine Hydrochloride